Philippine industry braces for more price cuts
This article was originally published in Scrip
The Philippine government is seeking a second round of price cuts for major prescription drugs following that last year, which saw the prices of 21 active ingredients slashed by up to 50%.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.